Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cabergoline, Placebo.
- Who it may be relevant to
- Registry conditions: Lactation Suppressed, Second Trimester Abortion. Basic parameters: 18 years — 50 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion: a Randomized Controlled Trial
Overview
The goal of this clinical trial is to compare breast symptoms (lactation, engorgement, etc) of individuals who undergo a procedure for second trimester of pregnancy loss between 16 weeks and 20 weeks gestational age. The participants will be randomly placed in two groups, one with a placebo tablet and one with medication called "cabergoline" which are taken immediately after their procedure. Researchers will compare groups to see if there are any significant differences in breast symptoms.
Interventions
- Drug Cabergoline
1mg oral cabergoline given to participants once - Drug Placebo
1 encapsulated placebo tablet given to participants after procedure
Primary outcome measures
- breast symptoms [Time frame: 3 days post procedure and two weeks post procedure]
Eligibility criteria
Inclusion criteria
- pregnant individuals seeking termination of pregnancy after 16w0d gestation and up to 19w6d gestation. this includes management of intrauterine demises
- ages 18 to 50
- con provide informed consent in English
Exclusion criteria
- Age under 18 or above 50
- gestational ages before 16 weeks 0 days or after 20 weeks 0 days
- unable to provide written consent in English
- hypertensive disorder
- uncontrolled hypertension or known hypersensitivity to ergot derivatives
- History of cardiac valvular disorders
- history of pulmonary fibrosis
- documented bipolar schizophrenia
- documented allergy to medication, including lactose intolerance (placebo pill involves lactose)
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Single blind
- Primary purpose
- Treatment
Study locations
United States · 1 center
- Northwestern Medical Center — Chicago
Identifiers
NCT: NCT06123026 · STU00218555